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Abstract 
Purpose: Combination of immune checkpoint inhibitors with chemotherapy is under 
investigation for cancer treatment. 
Experimental design: We studied the rationale of such a combination for treating mesothelioma, a 
disease with limited treatment options. 
Results: The combination of gemcitabine and immune checkpoint inhibitors outperformed 
immunotherapy alone with regard to tumor control and survival in a pre-clinical mesothelioma 
model; however, the addition of dexamethasone to gemcitabine and immune checkpoint 
inhibitors nullified the synergistic clinical response. Further, treatment with gemcitabine plus 
anti-PD-1 resulted in an objective clinical response in two mesothelioma patients, who were 
resistant to gemcitabine or anti-PD-1 as monotherapy. 
Conclusion: Thus, treatment of mesothelioma with a combination of gemcitabine with immune 
checkpoint inhibitors is feasible and results in synergistic clinical response compared to single 
treatment in the absence of steroids.  
 
Statement of significance: 
Mesothelioma is an aggressive cancer with few therapeutic options. Although immunotherapy 
might improve the course of the diseases, we are often confronted with the challenge of 
resistance. It is therefore of paramount importance to overcome such resistance and to improve 
patients’ outcome. We have demonstrated here the synergy of a chemotherapy (gemcitabine) and 
immune-checkpoint inhibitors in a preclinical model and in patients. These findings are essential 
for the design of new therapeutic approaches. 
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Introduction 
 
T cells can recognize and control transformed cells (1), however, protective immunity against 
cancer often is insufficient due to a plethora of immune escape mechanisms, including immune 
checkpoints such as programmed death receptor 1 (PD-1, CD279) (2). PD-1 is expressed on the 
surface of activated T cells (3) and interaction with its ligands PD-L1 (CD274, B7-H1) or PD-L2 
(CD273,  B7-DC) (4) results in T cell unresponsiveness (5). PD-L1 can be expressed by T and B 
cells, myeloid cells, endothelial cells and by various tumors (6), whereas the expression of PD-L2 
is limited to dendritic cells (DCs), macrophages and mast cells (4). 
Blockade of the interaction between PD-1 and its ligands has shown remarkable clinical 
responses in a proportion of patients with melanoma or non-small cell lung cancer (NSCLC) (7, 
8). Also in mesothelioma, treatment with immune checkpoint inhibitors (ICI) is promising with 
responses in about 20% (9) and disease control rate in 50% of patients (presented at ESMO 2017, 
Zalckman G., abstract LBA58_PR). Indeed, the efficacy of ICI in mesothelioma has been shown 
in different studies (9, 10), It is still a matter of debate whether the expression of PD-L1 by the 
tumor cells might be a useful predictive marker for survival or for clinical responsiveness to 
treatment with anti-PD-L1 (11-13). These discordant data may be explained by the difficulty to 
faithfully stain tumor samples for PD-L1, as well as the availability of multiple staining 
protocols, which hampered conclusive interpretations regarding the prognostic relevance of PD-
L1 expression in many cancer types including mesothelioma (14, 15).  
In this study, we show that the expression of PD-L1 by mesothelioma cells has prognostic power 
in a large cohort of mesothelioma patients. Furthermore, we demonstrate feasibility and efficacy 
of combining gemcitabine with ICI in a preclinical model for mesothelioma. We chose to 
combine gemcitabine with ICI because of its common use in mesothelioma and immune-
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stimulating effects (16-18). Finally, we tested this combination in two patients, who did not 
respond to pembrolizumab or gemcitabine as monotherapy, and observed clinical response in 
both cases. 
 
Materials and Methods  
 
Clinico-pathological characteristics of human mesothelioma samples 
Large sections from 145 mesothelioma patients were collected between 1999 and 2009. Patients 
received either a combination treatment with cisplatin/gemcitabine (with cisplatin on day 1 and 
gemcitabine on day 1 and 8, every three weeks) or cisplatin/pemetrexed (both on day 1, every 
three weeks). Post-chemotherapy tumor samples were collected after three cycles of treatment. In 
total, we collected 251 samples of which 147 were of the epithelioid, 14 of the biphasic and 90 of 
the sarcomatoid subtype. The 251 samples were collected as follows: 117 were surgical biopsies, 
132 were surgical specimens and 2 were needle-core biopsies. From those 251 samples, 118 were 
collected before and 133 after chemotherapy; 160 of these samples were matched samples from 
80 patients, taken before as well as after chemotherapy. From this cohort of 145 patients, 
matching samples of 80 patients before and after chemotherapy were available. Clinical data are 
summarized in Supplementary Table S1. All patients gave informed, written consent and the 
study was conducted in accordance with the declaration of Helsinki. The study was approved by 
the Institutional Ethical Review Board of the University Hospital Zurich under reference number 
StV 29-2009 and EK-ZH 2012-0094. 
 
Human mesothelioma tissue microarray 
Formalin-fixed paraffin-embedded (FFPE) blocks of the abovementioned samples were retrieved 
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from the archives of the Institute of Surgical Pathology, University Hospital of Zurich. All cases 
were reviewed by two pathologists (BV and VT) on full sections of a representative tumor block 
and classified following the definitions of the WHO classification for each subtype of 
mesothelioma. In case of biphasic mesothelioma, areas were identified that clearly separated the 
epitheloid and sarcomatoid growth patterns and 2 cores were taken from each area. 
Tissue microarrays (TMAs) were constructed with a custom-made, semiautomatic tissue array 
(Beecher Instruments, Sun Prairie, WI) as previously described (19, 20). The TMAs were built 
using at least two tissue punches with cores of 0.6 mm diameter for each patient using a Ventana 
ES instrument (Ventana Medical Systems, Baar, Switzerland) (21). TMA blocks were sectioned 
and stained with hematoxylin and eosin for morphologic assessment. Additional cores of control 
tissues, including 8 tonsils, 8 normal lung tissues, 8 normal pleura and 8 adenocarcinomas of the 
lung, were included in duplicate. Technical factors leading to loss of cores during TMAs 
processing (i.e., sectioning and staining) resulted in a reduction of the patient numbers available 
for subsequent statistical analysis. 
 
Human mesothelioma whole tumor sections 
In addition, we analyzed 20 matching whole tumor sections from 10 patients, taken before and 
after chemotherapy. These samples are included in the TMA described above. Those patients 
were treated with cisplatin (75 mg/m2 Q3W) plus pemetrexed (500 mg/m2 Q3W) as part of a 
clinical trial (22).  
 
Human mesothelioma cell lines and in vitro treatment 
The following human mesothelioma cell lines were used in this study: ZL55 (epitheloid), 
SPC111 (sarcomatoid) and MSTO-211H (biphasic). ZL55 and SPC111 were generated in our 
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laboratory (23) and MSTO-211H (24) was obtained from ATCC. Cells were cultured in 
humidified incubator at 37°C and 5% CO2 in either DMEM (for ZL55 and SPC11) or RPMI (for 
MSTO-211H) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine 
and antibiotics (all from Gibco). Cells were tested negative for Mycoplasma ssp. using the 
VenorGeM Mycoplasma detection kit (Sigma). 
Gemcitabine (Eli Lilly and Company), cisplatin (Sigma Aldrich) and pemetrexed (Eli Lilly and 
Company) were obtained from the local pharmacy and dissolved in phosphate-buffered saline 
(PBS).  Final concentrations in cell culture were as follows: gemcitabine, 0.1, 0.2, 0.5, 1 and 10 
µM; cisplatin, 0.01, 0.1 and 1 µM; pemetrexed, 0.1, 1 and 10 µM. The drug was added at the start 
of culture and once more after 24 h. Media was used as negative control (25). Analysis was 
performed 48 h after start of cultures. 
 
Mouse experiments 
C57BL/B6 mice were obtained from Harlan Laboratories (Envigo) and kept under specific 
pathogen-free conditions at the Laboratory Animal Services Center (LASC) of the University of 
Zurich. Six to eight weeks old female mice were used for all experiments. Experiments were 
performed in accordance with the Swiss federal and cantonal regulations on animal protection 
and were approved by the Cantonal Veterinary Office Zurich. 
RN5 cells are crocidolite-induced mesothelioma cells of C57BL/6 origin (26) (27). RN5 cells 
were tested negative for Mycoplasma ssp. using the VenorGeM Mycoplasma detection kit 
(Sigma). C57BL/6 mice were injected subcutaneously (s.c.) with 10
6
 RN5 cells in 100 μl 
phosphate-buffered saline (PBS). Tumor growth was measured every 3-4 days in two dimensions 
(length and width) with a caliper. When tumors reached a size of 40-50 mm
2
 (approximately 40 d 
after tumor cell injection), mice were randomized into different treatment groups and treatment 
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was started. The death event was defined as tumor size reaching the legally acceptable limit of 
225 mm
2
. 
Gemcitabine (Eli Lilly and Company) was dissolved in PBS and given intraperitoneally (i.p.) 
once per week at a dose of 120 mg/g body weight (28).  Anti–CTLA-4 (clone UC10-4F10-11) 
and anti-PD-1 (clone RMPI-14) were purified from culture supernatant using protein G 
Sepharose 4 Fast Flow (GE Healthcare) columns according to the manufacturer's protocol. 
Antibodies were administered i.p. once per week at 250 μg/100 μl PBS (29). Dexamethasone 
(Sigma-Aldrich) was administered orally (p.o.) once per week at 0.3 mg/kg body weight (30). All 
treatments were given on the same day. This experiment was repeated two times with at least 5 
mice/group.  
 
Flow cytometry and immunohistochemistry on cell lines 
Cultured cells were harvested by 0.5% Trypsin-EDTA treatment and stained with the following 
fluorophore-labeled monoclonal antibodies and appropriate isotype controls: PD-L1 (clone 
29E.2A3), PD-L2 (clone 24F.10C12), HLA-ABC (clone G46- 2.6), HLA-DR (clone L243). Dead 
cells were stained using Zombie Violet Fixable Viability Kit. Anti-HLA-ABC and anti-HLA-DR 
were obtained from BD Biosciences, all other reagents from BioLegend. Cells were incubated 
with appropriately diluted antibodies in PBS for 25 minutes at 4°C. Subsequently, cells were 
washed and fixed for 5 minutes with 2% paraformaldehyde in PBS. Samples were measured on a 
CyAn ADP9 machine (Beckman Coulter) and analyzed using FlowJo v9.8.5 software (Tree Star). 
For IHC, cell lines were pelleted after in vitro treatment, and formalin-fixed, paraffin-embedded, 
sectioned and subjected to immunohistochemistry for PD-L1 using clone E1L3N as described 
below under “Immunohistochemistry”. 
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Human patients treated with combination of gemcitabine with anti-PD-1 
The use of gemcitabine plus pembrolizumab was justified by the fact that both drugs are 
approved as monotherapy. The combination treatment was used off-label with written informed 
consent of the patients according to the declaration of Helsinki and was approved by the 
University Hospital Zurich. 
 
Immunohistochemistry  
Human samples 
For immunohistochemistry (IHC), 4 µm thick paraffin sections were cut from the TMA block 
and mounted on silane-coated glass slides. The sections were stained using an automated IHC 
platform (Ventana Benchmark). The following antibodies were used: anti-PD-L1 (E1L3N, Cell 
Signaling), anti-FOXP3 (236A/E7, Abcam), anti-CD3 (clone LN10, Leica Biosystems), anti-
Perforin (clone 5B10, DBS). Anti-PD-L1 staining with E1L3N antibody was performed by 
pretreatment of samples in H2O2 for 30 min and then samples were incubated with the antibody 
diluted as 1:1000 at room temperature for 30 min and heat-induced epitope retrieval HIER2 
solution with a Bond Polymer Refine Detection kit (Leica Biosystems). Samples with <50 
evaluable cells were excluded. Biopsies were considered PD-L1
+
 when >1% of tumor cells were 
stained positive with anti-PD-L1. Comparison of PD-L1 staining using either the clone E1L3N 
from Cell Signaling or the clone SP142 from Ventana showed a correspondence in 100% of cases 
either negative or positive (Supplementary Figure S1). Each core was evaluated independently by 
two pathologists (DS and VT). We used archived FFPE samples. Although the use of archival 
FFPE samples to determine PD-L1 expression in mesothelioma has not yet been validated, it was 
shown that matching fresh and FFPE lung cancer samples gave similar results regarding PD-L1 
expression determined by IHC (31).  
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Murine samples 
Resected tumors were processed for FFPE and 4 µm thick sections were stained for IHC by 
Sophistolab AG (Muttenz, Switzerland) using a Leica BondMax instrument and Refine HRP-Kits 
(Leica DS9800, Leica Microsystems Newcastle) according to the manufacturer’s guidelines. The 
following antibodies were used: PD-L1 (Lifespan LS-B9795), FoxP3 (Novus Biologicals, NBP1-
18319), CD3 (RMAB005, clone SP7, DBiosystem). Hematoxylin counterstaining was performed 
according to standard protocol. Whole slides were scanned with a Zeiss Mirax Midi slide scanner 
(20x objective, NA0.8) equipped with a 3-CCD color camera (Hitachi HV-F22) and analyzed 
using Pannoramic viewer 1.15.4 (3DHISTECH).  
 
Survival Analysis 
The Kaplan-Meier method was used to estimate tumor-specific overall survival (OS). Tumor-
specific OS in humans was determined from the date of histological diagnosis of mesothelioma to 
the date of death from the same cancer up to 5 years of follow-up. Patients, who were alive at the 
time of last follow-up were censored for OS analysis. Continuous data were compared between 
groups using the Mann-Whitney U test. For comparison of experimental groups, two-tailed 
Student’s t-test with Welch’s correction was performed. Statistical significance p<0.05. 
Statistical analyses were performed using IBM SPSS Statistics 20.0 (SPSS Inc, Chicago IL) 
For mice, tumor-specific OS was determined from the date of randomization and the death event 
was defined as tumor size reaching the legally acceptable limit of 225 mm
2
. For survival analysis, 
the Log-rank Test (Mantel Cox test) was used. For comparison between each experimental 
groups ANOVA with Bonferroni correction was performed. Statistical analyses were performed 
using PRISM (GraphPad Prism version 7 for Mac, GraphPad Software, La Jolla California USA). 
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Results 
 
Expression of PD-L1 by human mesothelioma is a negative prognostic biomarker for 
survival  
We investigated the expression of PD-L1 in a cohort of 145 mesothelioma patients 
(Supplementary Table S1). Tumor samples were available from 100 cases before chemotherapy 
and 122 cases after chemotherapy; 80 of these cases were paired samples taken from the same 
patient before and after chemotherapy. We detected expression of PD-L1 in 14% of samples 
before chemotherapy (14 out of 100) and in 18% of cases after chemotherapy (22 out of 122) 
(Supplementary Table S2); expression of PD-L1 was membranous and homogenous, and the 
intensity of expression varied from low (+) to high (+++) (Figures 1A and 1B). We found that 
expression of PD-L1 on tumor cells was a negative prognostic marker (p=0.04) for survival 
independent of both the histological subtype and other clinical features (Figure 1C). 
Using large sections, we detected CD3
+
 T cells throughout the tumor tissue, but none of them 
expressed perforin. Instead, most of the CD3
+
 T cells expressed FOXP3
+
 and were preferentially 
localized in PD-L1
+
 tumor areas (Supplementary Figure S2).  
 
Chemotherapy does not influence PD-L1 expression by human mesothelioma  
To investigate whether chemotherapy with cisplatin/pemetrexed or cisplatin/gemcitabine has an 
impact on the expression of PD-L1 by mesothelioma cells, we compared the expression of PD-L1 
in paired samples taken before and after chemotherapy from 80 patients. Although we found that 
the PD-L1 expression differed between matched samples, these changes seemed random 
(Supplementary Table S2), suggesting that the chemotherapies investigated here had no 
straightforward impact on PD-L1 expression. From the cohort of 80 paired samples taken before 
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and after chemotherapy, we further analyzed 20 large sections (i.e. paired samples from 10 
patients) for expression of PD-L1 on tumor cells and confirmed the data described above (not 
shown).  
To directly address whether chemotherapeutic drugs influence the expression of PD-L1 on 
mesothelioma cells, we incubated two human PD-L1
+
 mesothelioma cell lines (MSTO and 
SPC11) and one human PD-L1
-
 mesothelioma cell line (ZL55) with gemcitabine or 
cisplatin/pemetrexed. We did not observe chemotherapy-induced changes with respect to PD-L1 
expression by FACS in any of the cell lines (Figure 2). To further validate our data, we made cell 
blocks of the previously mentioned conditions and perform IHC for PD-L1 (Supplementary 
Figure S3).  There was a complete correlation between FACS and IHC for MSTO (positive) and 
ZTL55 (negative) cell lines (either untreated, treated with gemcitabine or treated with 
cisplatin/pemetrexed). The SPC11 cell line (positive by FACS) was weakly positive only in one 
out of the three samples (untreated, treated with gemcitabine or treated with 
cisplatin/pemetrexed). This is consistent with reports showing variation among different PD-L1 
antibodies (32) and that PD-L1 analysis by FACS and IHC is not fully overlapping (33).  
Together these data suggest that neither cisplatin/pemetrexed nor cisplatin/gemcitabine induce 
direct changes in PD-L1 expression by mesothelioma cells. Rather, we think that the random 
differences observed between paired samples may be explained by intratumoral heterogeneity 
regarding PD-L1 expression or by indirect effects of chemotherapy, For example, some 
chemotherapies including cisplatin and doxorubicin induce immunogenic cell death and result in 
local stimulation of tumor-specific immunity (34) and this will produce interferon-γ (IFN-γ) at 
the tumor site. PD-L1 expression over time could be then the result of local IFN-γ production 
(35). Furthermore, our data suggest that standard of care chemotherapy does not per se preclude 
subsequent treatment with PD-1 blocking antibodies.  
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Gemcitabine plus immune checkpoint has better efficacy than gemcitabine or immune 
checkpoint inhibitors as monotherapy in mice  
To investigate whether gemcitabine synergizes with ICI, we used a mouse mesothelioma model, 
subcutaneous RN5 tumors in syngeneic C57BL/6 mice. This model shares histopathologic 
features with the aggressive human mesothelioma subtype (sarcomatoid). We found that 
treatment with gemcitabine impeded tumor progression and promoted infiltration by CD3
+
 T 
cells, whereas treatment with ICI had no significant impact on tumor progression or survival.  
The combination of gemcitabine and ICI, however, significantly prolonged survival and resulted 
in tumor rejection in a proportion of the mice (Figures 3A and 3B), suggesting a synergistic effect 
of ICI plus gemcitabine. 
 
Corticosteroids nullify the synergy of chemo- and immunotherapy in mice 
Dexamethasone is an anti-inflammatory and immunosuppressive glucocorticoid that is commonly 
used together with chemotherapy as an anti-emetic drug. Specifically, dexamethasone is often 
given with gemcitabine in order to prevent side effects including chemotherapy-induced nausea 
and vomiting, fever and chills. In contrast to brief treatment schedules, long-term use of 
glucocorticoids is immunosuppressive (24). We observed a therapeutic synergy when ICI was 
combined with gemcitabine, suggesting that activation of immune defense supports the clinical 
response to gemcitabine. Therefore, we wondered whether long term treatment with 
dexamethasone would negatively influence this therapeutic synergy and treated mice with 
established RN5 tumors with gemcitabine plus ICI or gemcitabine plus ICI plus dexamethasone. 
Mice treated with gemcitabine alone or vehicle served as controls. Again, we observed that 
gemcitabine plus ICI resulted in significantly better survival compared to gemcitabine alone 
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(Figure 3B). However, addition of dexamethasone to the treatment with gemcitabine plus ICI 
significantly reduced responses in treated mice (Figure 3B). Next, we investigated the immune 
infiltrate in mouse mesothelioma by immunohistochemistry for CD3 and FoxP3 at the endpoint. 
We observed increased fibrotic and necrotic areas after treatment with gemcitabine plus ICI, as 
well as increased number of infiltrating CD3
+
 T cells compared to all other groups (Figure 4). 
Furthermore, none of the CD3
+
 cells expressed FoxP3 (data not shown). In contrast, tumors of 
mice treated with gemcitabine plus ICI plus dexamethasone did not show necrotic areas and very 
few infiltrating CD3
+
 T cells (Figure 4), suggesting that corticosteroids negatively influence the 
clinical response to gemcitabine plus ICI. We think that this may apply to any other therapy that 
involves immune stimulation including standard therapies (36) (37), suggesting that the use of 
steroids in the context of cancer therapies should be avoided if possible. It may very well be of 
general applicability that clinical responses to ICI are stronger in absence of steroids. The finding 
that concomitant use of steroids was associated with poor outcomes of NSCLC patients treated 
with ICI (38) supports this idea.   
 
The combination of gemcitabine with anti-PD-1 can overcome the resistance to ICI in 
patients 
Currently, the standard of treatment of mesothelioma is chemotherapy. However, blockade of the 
interaction between PD-1 and its ligands has shown promising clinical responses in a proportion 
of patients in clinical trials (9). We present here two patients with mesothelioma who were 
refractory to various therapies but responded to a combination of anti-PD-1 and gemcitabine. 
The first patient was 66 years old and diagnosed with epithelioid mesothelioma three years ago 
(in 2014). The patient underwent multimodality approaches including chemotherapy and tumor 
resection. Due to relapse of disease, the patient was treated with pembrolizumab. Upon 
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progression, the patient was treated with carboplatin/pemetrexed. Then he was switched to 
carboplatin/gemcitabine and consecutively to gemcitabine monotherapy. Due to further 
progression, the patient received a combination of gemcitabine (1000 mg/m
2
 weekly) plus 
pembrolizumab (200 mg every 3 weeks) without corticosteroids. Before starting this treatment, 
the patient complained about dysphagia and weight loss. However, two months after starting this 
combination treatment, the patient could eat normally and a radiological and metabolic response 
to treatment was detected (Figures 5A and 5B). He is still under therapy, 20 weeks after start of 
treatment. 
The second case was a 57-year-old patient diagnosed with epithelioid mesothelioma 4 years ago 
(in 2013). The patient underwent multimodality approaches including chemotherapy and tumor 
resection (Figure 5C). Due to recurrence of disease in 2016, the patient was treated with 
pembrolizumab (anti-PD-1), which resulted in progression of disease (Figure 5D, time point i), 
and subsequently with carboplatin/pemetrexed with further progression of disease (Figure 5D, 
time point ii). Then one symptomatic lesion in the chest wall was irradiated with a total dose of 
36 Gy (6 x 6 Gy).  Restaging was performed (Figure 5D, time point iii) before start of weekly 
chemotherapy with gemcitabine (without corticosteroids). Within two months of gemcitabine 
monotherapy there was evidence of progression of the mediastinal mass and lung metastasis 
(Figure 5D, time point iv) and the patient had a reduced performance status with ECOG 3 due to 
cachexia and dyspnea. Because the patient did not show any limiting side effects on gemcitabine, 
we started a treatment with pembrolizumab (200 mg every three weeks) and gemcitabine (1000 
mg/m
2
 weekly), in March 2017. After three cycles of this treatment, the patient clinically 
improved and went back to work using his bicycle as means of transport. Furthermore, 
radiological images showed a clinical response of the mediastinal mass and lung metastasis with 
increased pleural effusion (Figure 5D, time point v). We observed no side effects besides grade 2 
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anemia and pleural effusion that was drained after treatment. We analyzed the composition of the 
pleural effusion and observed that together with few mesothelioma cells there was 80% of 
lymphocytes (Figures 6A and 6B), of these, 90% were CD3
+
 T cells, consisting of 20% CD4
+
 
(Figure 6C) and 75% CD8
+ 
cells (Figure 6D). This suggests that the combination of gemcitabine 
plus anti-PD-1 mobilized protective immunity resulting in an objective clinical response. Because 
of his improved general condition, the patient wished to stop the treatment and undertake a 
journey of five weeks. Upon his return, treatment with gemcitabine plus anti-PD-1 was started 
with a three-weekly schedule for both medications as per the patient’s request. After two cycles 
of this treatment, a progression of disease was detected and the treatment was discontinued. 
 
Discussion 
 
Combining different therapies for cancer is a promising approach to overcome resistance and 
improve responses. For example, combination of nivolumab (anti-PD-1) with ipilimumab (anti-
CTLA-4) has shown improved clinical responses compared to monotherapy, however, also 
increased side effects (39). Currently, combinations of different chemotherapies with 
immunotherapy are under evaluation for different tumor types (NCT02039674, NCT02366143). 
We investigated whether the combination of gemcitabine with ICI is an effective and feasible 
treatment for mesothelioma that outperforms monotherapy and may even overcome resistance to 
monotherapy. 
Expression of PD-L1 by tumor cells is often used as inclusion criterion for treatment with 
antibodies that block the interaction of PD-1 with its ligands (9). Therefore, we first investigated 
whether gemcitabine influences the expression of PD-L1 by mesothelioma cells in vivo and in 
vitro. In addition, we found that the expression of PD-L1 is a negative biomarker for survival in 
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mesothelioma, which goes in line with previous studies (40) (14) and with data obtained from 
other tumor entities (41) (42) (43) (44). 
We found that treatment with gemcitabine plus ICI significantly prolonged survival of 
mesothelioma-bearing mice compared to gemcitabine alone, whereas ICI as monotherapy had no 
impact. Although ICI as monotherapy shows clinical efficacy in mesothelioma patients (45), this 
is not the case in our preclinical model. Absence of clinical efficacy of ICI as monotherapy has 
been described in multiple mouse models (29) but this discrepancy with humans is not 
understood.  
Corticosteroids are commonly used to manage side effects of chemotherapy. Because of their 
immunosuppressive properties, we evaluated the impact of dexamethasone on the clinical 
efficacy of gemcitabine plus ICI and observed an abrogation of therapeutic synergy. This 
suggests that side effects of chemotherapy should be managed by other medications than 
corticosteroids, whenever possible. Indeed, we have successfully applied this approach to both 
patients presented here.  
Our data show that PD-L1 expression is heterogeneous and prone to immune response-induced 
changes. In addition, various studies have shown a high degree of intratumoral heterogeneity in 
PD-L1 expression in different cancers (46) (47). Therefore, we think that using PD-L1 expression 
as an inclusion criterion for treatments targeting this pathway is not sufficiently justified for 
mesothelioma patients. We demonstrated the synergy of gemcitabine with ICI providing a 
rationale for a clinical trial that can include patients with different tumor types, where 
gemcitabine represents a standard of care and might be favorable in terms of tolerability and costs 
compared to combination of several immunomodulating agents. It has been shown that in patients 
with advanced lung cancer that daily administration of steroids reduces lymphocyte numbers (48) 
and may be associated with worse outcome (38). Obviously, highly emetogenic treatments must 
Research. 
on October 18, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 28, 2018; DOI: 10.1158/1078-0432.CCR-18-1231 
 17 
be combined with anti-emetic drugs, however, corticosteroids should be avoided and established 
alternatives used instead. Here, we show in a pre-clinical model that avoiding the use of 
dexamethasone improves the efficacy of immunotherapy for mesothelioma, a disease with very 
limited effective treatment options (49) and an unmet need for new therapies (50). 
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Figure legends 
 
Figure 1. PD-L1 is a negative prognostic marker for mesothelioma patients. 
PD-L1 Expression in mesothelioma tumor samples. (A) Representative example of negative 
expression. (B) Representative example of positive expression (brown). The expression of PD-L1 
was homogeneous within a core of the TMA.  (C) Overall survival data for patients with PD-L1-
positive versus -negative mesothelioma. The PD-L1 negative patients had a median survival of 
20.7 months (95% CI, 16.8-24.5 months), the PD-L1 positive patients of 8.8 months (95% CI, 
0.9-16.6 months). Continuous data were compared between groups using the Mann-Whitney U 
test. 
 
Figure 2. Chemotherapy does not change the expression of PD-L1 on human mesothelioma 
cell lines in vitro. 
MSTO, ZL55 and SPC11 cells were treated in vitro with 0.2 µM gemcitabine or 0.1 µM 
cisplatin/1 µM pemetrexed for 48 h. Surface PD-L1 expression was determined by flow 
cytometry. Cells cultured in media served as control. PD-L1 expression on untreated cells is 
displayed in light red, after chemotherapy in dark red. Staining with isotype controls of untreated 
and chemotherapy-treated cells is displayed in light and dark grey, respectively.  
 
Fig 3. Gemcitabine plus ICI significantly prolongs the survival of mesothelioma-bearing 
mice. Female C57BL/6 mice were injected s.c. with 10
6
 syngeneic RN5 mesothelioma cells. 
Mice were randomized into treatment groups as soon as tumors reached a size of 40-50 mm
2
 
(appr. 40 d after tumor cell injection). Mice were treated as follows: (A) Untreated (n=4); 
Gemcitabine (Gem, n=5); anti-CTLA4 + anti-PD1 (ICI, n=5); Gem + ICI (n=4), or (B) Untreated 
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(n=6); Gem (n=6); Gem + ICI (n=7); Gem + ICI + Dexa (Dexamethasone, n=7). Statistical 
analysis was performed using a Log-rank test (Mantel-Cox test). *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  The experiments depicted in panel A and B were performed 
independently and represent one experiment repeated two times. 
 
Figure 4. Gemcitabine plus immune checkpoint inhibitors synergize to induce tumor cell 
death and infiltration by CD3
+
 cells. 
Representative immunohistochemical staining of CD3
+
 cells in tumor samples from mice 
described in Figure 4B.  
 
Fig 5. Response to pembrolizumab and gemcitabine in two patients with mesothelioma.  
Panels A-B, patient 1; panels C-D, patient 2. (A) Timeline of the treatments. (B) Quantification 
of the response to the treatments by PET/CT scan at 5 different timepoints (1-5), black arrow 
marks the start of gemcitabine + pembrolizumab therapy. Performance status was evaluated by 
Eastern Cooperative Oncology Group (ECOG) scale. MTV stands for metabolic tumor volume. 
Lower panel shows representative pictures of whole body PET/CT scan at the corresponding 5 
timepoints. (C) Timeline of the treatments. (D) Quantification of the response to the treatments 
by CT scan 5 different time points (i-v), black arrow marks the start of gemcitabine + 
pembrolizumab therapy. Performance status was evaluated by Eastern Cooperative Oncology 
Group (ECOG) scale. Lower panel shows representative pictures of the CT scan of the 
mediastinum at the corresponding 5 time points. Mediastinal lesion is marked with a white 
asterisk. White arrow marks the pleural effusion. Lung metastasis in the left upper lower that 
appeared after radiotherapy (time point iii) is shown in the inlet, marked with a black circle.   
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Figure 6. Cytological analysis of the pleural fluid from patient 2.  
Pleural fluid of patient 2 was collected from the lesion shown in Figure 6.2 E and the sediment 
was analyzed by cytology. (A) Papanicolooau staining revealed the presence of mesothelioma 
cells (black arrows), numerous lymphocytes (red arrows) and few macrophages and neutrophilic 
granulocytes in the background (original magnification 400x). Mesothelioma cells were 
calretinin
+
, desmin
-
, BAP1
-
 (data not shown). (B) CD3 immunostaining revealed that 90% of 
lymphocytes were CD3
+
 T-cells (brown signal; original magnification 400x). (C, D) Flow 
cytometric analysis showed that 20% of CD3
+
 T-cells express CD4 (panel C) and 75% express 
CD8 (panel D).  
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